Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × sacituzumab govitecan × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Triple Negative Breast Neoplasms 15 Carcinoma, Non-Small-Cell Lung 6 Lung Neoplasms 4 Carcinoma, Transitional Cell 4 Urinary Bladder Neoplasms 3 Neoplasm Metastasis 3 Brain Neoplasms 3 Salivary Gland Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Metastatic Urothelial Cancer 1 Laryngeal Neoplasms 1 Klatskin Tumor 1 Hypopharyngeal Neoplasms 1 Head and Neck Neoplasms 1 HER2-negative Breast Cancer 1

Interventions

Temozolomide 154 Bevacizumab 88 Radiotherapy 75 Radiation 23 Magnetic Resonance Spectroscopy 23 Lomustine 18 Irinotecan 18 pembrolizumab 17 Surgical Procedures, Operative 16 Carmustine 16 Erlotinib Hydrochloride 12 Nivolumab 11 Specimen Handling 10 Aminolevulinic Acid 10 sargramostim 9 Thalidomide 9 Chemotherapy, Adjuvant 9 Carboplatin 9 Immunoglobulin G 7 Filgrastim 7 Etoposide 7 Drug Therapy 7 Disulfides 7 Cilengitide 7 Sunitinib 6 Sorafenib 6 O(6)-benzylguanine 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04559230 2026-03-30

Sacituzumab Govitecan in Recurrent Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡